Search

Displaying results 451 - 460 of 10000 in total
  1. Drug

    4-Nitrocatechol

    go.drugbank.com/drugs/DB03407
    Experimental

    Synonyms: 4-Nitrocatechol
  2. Drug

    4-Fluorobenzylamine

    go.drugbank.com/drugs/DB03243
    Experimental

    Synonyms: 4-Fluorobenzylamine
  3. Drug

    4-Fluorotryptophane

    go.drugbank.com/drugs/DB03386
    Experimental

    Synonyms: 4-Fluorotryptophane
  4. Drug

    Furosemide

    go.drugbank.com/drugs/DB00695
    ApprovedInvestigationalVet approved

    [A182495] The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. … Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients.

    Mixtures: Lasitace 5 mg/40 mg Kapseln, Lasitace 5 mg/20 mg KapselnSynonyms: 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid, 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
  5. Drug

    N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide

    go.drugbank.com/drugs/DB07152
    Experimental

    Synonyms: N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  6. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    [A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

    Synonyms: 6-(3,4-Dimethoxyphenyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]-4-quinazolinamine
  7. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE
  8. Drug

    N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo(d)imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-amine

    go.drugbank.com/drugs/DB18299
    Investigational

    Synonyms: N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo(d)imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-amine
  9. Drug

    Flurbiprofen

    go.drugbank.com/drugs/DB00712
    ApprovedInvestigational

    Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.

    Mixtures: FULDUO 100 MG/8 MG FİLM KAPLI TABLET, 14 ADET, MULTIFLEX 200/8 MG SR KAPSUL, 14 ADETCategories: Cytochrome P-450 Substrates, Non COX-2 selective NSAIDS
  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).